Biogen gets much-needed pipeline lift with speedy ALS drug review
Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months. The priority review of the Ionis-partnered SOD-1-targeted antisense drug marks the latest stage in the resurrection of the programme, which was all-but written off last October …
Biogen gets much-needed pipeline lift with speedy ALS drug review Read More »